Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Scientists find a new pharmacological target to modulate the effect of cannabinoids through their CB1 receptors

05.07.2012
A group or researchers from the Faculty of Biology of the University of Barcelona and the Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), a centre for biomedical network research on neurodegenerative diseases dependant on the Ministry of Economics and Competitiveness through the Carlos III Health Institute, has shown, in a research published in the Journal of Biological Chemistry, the expression of complexes known as heteromerswithin the cannabinoid receptors CB2 and CB1.
The results of this research may help in the better understanding of alterations where the CB1 receptor participates, such as in chronic pain, Parkinson's disease, cerebral trauma or brain tumours in which there may be a high inflammatory component.

Cannabis, commonly known as marihuana, is one of the most widely abused drugs among the European population. Its psychoactive substances act by interacting with proteins from the membrane of the cells which are their CB1 and CB2 receptors. In a natural way and independent of the marihuana, the cells themselves release compounds which are called endocannabinoids and they activate the CB1 and CB2 receptors to produce a physiological response.

The CB1 cannabinoid receptor is one of the most abundant receptors in the brain and it helps to regulate movement, as well as functioning as a therapeutic target for the treatment of pain, inflammation and Parkinson's disease, and it alleviates some side effects in cancer patients. Nevertheless, the CB2 cannabinoid receptors are far from being abundant in the brain and their function is not completely clear. This makes these receptors a subject of scientific interest, precisely because of the scarcity of information regarding their functioning.

The existence and function of the CB2 receptors in the neurons has always been controversial. This new research now offers two relevant conclusions: in the first place, the expression of CB2 as a protein in the neurons is confirmed and, in the second place, it is shown that the CB2 receptors may be a new pharmacological target for the modulation of the effect of cannabinoids through the CB1 receptor, forming CB1-CB2 heteromers which are expressed in the brain. The mission of CB2 in these heteromers is to repress the CB1 receptors, which could explain that during processes of inflammation, the CB2 receptors act as a brake on the CB1 receptors.

The research shows that it is necessary to take these heteromers into account for the effective design of medicines to counteract cannabinoid receptors, since these heteromers are the real targets and they show properties that are different from the individual receptors. This project has been carried out by the Molecular Neurobiology Research Group from the University of Barcelona, integrated in the campus of international excellence Barcelona Knowledg Campus (BKC), and the following lecturers worked on it: Dr. Peter McCormick, Dr. Enric I. Canela, Dr. Antoni Cortés, Dr. Carme Lluís, Dr. Josefa Mallol, Dr. Vicent Casadó, Dr. David Moreno-Delgado and Dr. Estefanía Moreno and the doctoral student Lucía Callén. Also participating in the project were Dr. José Luis Lanciego and Dr. Rafael Franco from the University of Navarra.

Parkinson's disease affects around 70,000 people in Spain

Neurodegenerative diseases (NDD) represent one of the most important health challenges in developed countries, because of their consequences for health and quality of life of those who suffer from them, as well as the socioeconomic burden that they represent. They are generally chronic, for the moment incurable, diseases and their common denominator is the death of neurons in different regions of the nervous system, which leads to the functional deterioration of the affected parts. In the case of Parkinson's disease, there are 70,000 people affected in Spain and the disease is characterized principally by the loss of neurons and the formation of Lewy bodies and Lewy neurites in the black substance and the consequent loss of striatal dopamine (DA). Nevertheless, it is currently well known that Parkinson's disease is a multisystemic neurodegenerative process, in which, as the neurodegenerative process evolves, numerous regions of the nervous system are affected and there exists a deficit in various systems of neurotransmission and neuromodulation.

The Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED) is one of the reference centres in Spain for research on neurodegenerative diseases (NDD), such as Alzheimer’s, Parkinson’s, Huntington’s diseases and other ataxias and neuromuscular diseases. It was created in 2006 and its main objective is to promote basic biomedical, clinical and epidemiological research, as well as to ensure that the research carried out in laboratories can be put into practice and reach the patient (translational research). Legally it is organised as a public consortium where various institutions representing the Spanish General State Administration, the Spanish Autonomous Communities and other non-institutional organisations take part. It gathers a total of 58 Spanish research groups that share a common goal: the fight against neurodegeneration.
Bibliographische AngabenCannabinoid Receptors CB1 and CB2 Form Functional
Heteromers in Brain. Lucía Callén, Estefanía Moreno, Pedro Barroso-Chinea, David Moreno-Delgado, Antoni Cortés,

Josefa Mallol, Vicent Casadó, José Luis Lanciego, Rafael Franco, Carmen Lluis, Enric I. Canela, and Peter J. McCormick.

THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 287, NO. 25, pp. 20851–20865, June 15, 2012

Hinweise an die RedaktionFurther information:

Dr. Peter McCormick
Dept. Bioquímica i Biologia Molecular (Biologia)
Facultat de Biologia - UNIVERSITAT DE BARCELONA
Tf 00 34 934039280
mailto: pmccormick@ub.edu

Rosa Martínez | alfa
Further information:
http://www.ub.edu

More articles from Life Sciences:

nachricht Molecular Force Sensors
20.09.2017 | Max-Planck-Institut für Biochemie

nachricht Foster tadpoles trigger parental instinct in poison frogs
20.09.2017 | Veterinärmedizinische Universität Wien

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Tiny lasers from a gallery of whispers

New technique promises tunable laser devices

Whispering gallery mode (WGM) resonators are used to make tiny micro-lasers, sensors, switches, routers and other devices. These tiny structures rely on a...

Im Focus: Ultrafast snapshots of relaxing electrons in solids

Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!

When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...

Im Focus: Quantum Sensors Decipher Magnetic Ordering in a New Semiconducting Material

For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.

Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...

Im Focus: Fast, convenient & standardized: New lab innovation for automated tissue engineering & drug

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems Holding GmbH about commercial use of a multi-well tissue plate for automated and reliable tissue engineering & drug testing.

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems...

Im Focus: Silencing bacteria

HZI researchers pave the way for new agents that render hospital pathogens mute

Pathogenic bacteria are becoming resistant to common antibiotics to an ever increasing degree. One of the most difficult germs is Pseudomonas aeruginosa, a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

Molecular Force Sensors

20.09.2017 | Life Sciences

Producing electricity during flight

20.09.2017 | Power and Electrical Engineering

Tiny lasers from a gallery of whispers

20.09.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>